Any current/future new fundraising through debt or equity?

Quick Heal Technologies currently holds a strong balance sheet with INR 191 crores cash and investments as of September 30, 2025. Management has not disclosed any immediate plans for new fundraising through debt or equity. They continuously evaluate options for investments, including potential M&A or acquisitions, and will update investors as appropriate. Any deployment of cash reserves for growth or acquisitions will be aligned with company strategy and board approval. There is no specific mention of raising fresh funds through debt or equity in the current quarter or near future from the pro

Any current/future capex/capital investment/strategic investment?

The company maintains a strong balance sheet with INR 191 crores cash balance as of 30th September 2025, offering flexibility for investments. They are actively evaluating options for M&A and strategic acquisitions aligned with their vision and roadmap. Investments in R&D remain a priority, with ongoing optimization through AI and automation to sustain product innovation. There are no specific disclosed plans for large current capex, but the firm continues expanding sales and marketing teams, especially for Enterprise growth. The company is focused on leveraging government and international ma

Future growth expectations in sales/revenue/volumes?

Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining. Total Addressable Market (TAM) is projected to increase from INR 1,800 crores to INR 4,000 crores. Enterprise segment expected to contribute around 80% of the INR 4,000 crores TAM; Consumer around 20%. International revenue currently constitutes about 20% of Enterprise revenue. Government segment and international markets targeted for significant growth. New products such as data privacy solutions, threat intelligence platforms, EDR, XDR, STI, and SMAP

Future growth expectations in earnings/operating earnings/profits/EPS?

Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split). Enterprise segment, especially mid-market and government sectors, is a key growth lever with increasing traction in products like EDR, XDR, STI, and SMAP. Revenue for Q2 FY26 grew 14% YoY to INR 83.5 crores with an EBITDA margin of around 11%. R&D investments are ongoing but optimized using AI and automation; these expenses are expensed fully and impact EBITDA. Management is cautious on giving specific revenue/EPS

IN US

Sale is live|00:00:00left today

Quick Heal Technologies LtdQ3 FY25IT - Software

Quick Heal Technologies Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹177P/E: 196.4Market Cap: ₹1.1K CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining.
→Total Addressable Market (TAM) is projected to increase from INR 1,800 crores to INR 4,000 crores.
→Enterprise segment expected to contribute around 80% of the INR 4,000 crores TAM; Consumer around 20%.
→International revenue currently constitutes about 20% of Enterprise revenue.
→Government segment and international markets targeted for significant growth.
→New products such as data privacy solutions, threat intelligence platforms, EDR, XDR, STI, and SMAP expected to drive growth.
→Focus on mid-market and SMB enterprises with 1,000-5,000 endpoints.
→Continued investments in R&D and sales/marketing to support revenue growth.
→Consumer business revenue will largely remain stable, aiming to hold market share amid decline.
→Revenue for Q2 FY ’26 was INR 83.5 crores, showing healthy growth compared to prior periods.

Margin guidance

Category 3

→Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split).
→Enterprise segment, especially mid-market and government sectors, is a key growth lever with increasing traction in products like EDR, XDR, STI, and SMAP.
→Revenue for Q2 FY26 grew 14% YoY to INR 83.5 crores with an EBITDA margin of around 11%.
→R&D investments are ongoing but optimized using AI and automation; these expenses are expensed fully and impact EBITDA.
→Management is cautious on giving specific revenue/EPS guidance but expects that increased enterprise revenue and operational efficiencies will improve margins and profitability.
→Marketing and sales investments, especially for Enterprise, will continue proportional to revenue growth.
→Government sector and international markets (20% of revenues) represent significant growth opportunities.
→Overall, longer-term profitability is expected to improve as Enterprise segment scales and R&D investments yield product benefits.

3 more insights locked — sign up free to unlock

Fundraise plans

→Quick Heal Technologies currently holds a strong balance sheet with INR 191 crores cash and investments as of September 30, 2025.
→Management has not disclosed any immediate plans for new fundraising through debt or equity.
→They continuously evaluate options for investments, including potential M&A or acquisitions, and will update investors as appropriate.
→Any deployment of cash reserves for growth or acquisitions will be aligned with company strategy and board approval.
→There is no specific mention of raising fresh funds through debt or equity in the current quarter or near future from the provided transcript.

Order book

The transcript does not specifically disclose current or expected orderbook or pending orders figures. However, some related points include: - The company has a "heavily business pipeline" and a growing international presence, indicating a healthy flow of prospective deals. - Government business is showing robust growth with some delays due to big-ticket decision timelines. - Enterprise business continues steady growth with strong partners and traction across key segments. - New products like data privacy solutions and threat intelligence platforms are gaining initial interest. - The company is actively pursuing government and international opportunities under Make in India initiatives. - Enterprise segment, especially mid-market and government, is expected to be a key lever for growth over the next 2-3 years. No explicit orderbook or pending order values are mentioned.

Capex plans

Yes

→The company maintains a strong balance sheet with INR 191 crores cash balance as of 30th September 2025, offering flexibility for investments.
→They are actively evaluating options for M&A and strategic acquisitions aligned with their vision and roadmap.
→Investments in R&D remain a priority, with ongoing optimization through AI and automation to sustain product innovation.
→There are no specific disclosed plans for large current capex, but the firm continues expanding sales and marketing teams, especially for Enterprise growth.
→The company is focused on leveraging government and international market opportunities, especially through Make in India initiatives, but concrete capex figures or timelines were not detailed.
→Overall, capital allocation is strategically measured to balance growth in Enterprise and Consumer businesses and continuous R&D investments.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

1Quick Heal Technologies Ltd

Rev 3Mar 3

See full IT - Software sector rankings

Want more stocks like Quick Heal Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio